Skip to main
AGL
AGL logo

Agilon Health (AGL) Stock Forecast & Price Target

Agilon Health (AGL) Analyst Ratings

Based on 22 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 55%
Sell 9%
Strong Sell 0%

Bulls say

Agilon Health Inc demonstrated significant growth, with total revenue increasing by 44.2% year-over-year in the fourth quarter, surpassing initial estimates. The company's Medicare Advantage (MA) membership expanded by 36% year-over-year, reaching 527,000 members, supported by a 4.1% growth in the same geography during the quarter. Improvements in medical cost data and operating expenses, which came in lower than expected, further underlie the company's positive trajectory and potential for sustainable financial performance.

Bears say

Agilon Health has demonstrated ongoing visibility issues, particularly evident in the second half of the year, which resulted in negative surprises regarding financial forecasts due to challenges with utilization. In the fourth quarter of 2024, the company reported an adjusted EBITDA loss of $(84.0) million, falling short of expectations and reflecting lower medical margins, notably a significant decrease from prior estimates. Additionally, the guidance for ACO REACH patients projected a 12.9% to 20.5% quarter-over-quarter decline, signaling potential challenges in growth and margins that contribute to an overall negative financial outlook.

Agilon Health (AGL) has been analyzed by 22 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 55% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agilon Health (AGL) Forecast

Analysts have given Agilon Health (AGL) a Hold based on their latest research and market trends.

According to 22 analysts, Agilon Health (AGL) has a Hold consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agilon Health (AGL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.